Use of Radiation in Extramedullary Leukemia/Chloroma: Guidelines From the International Lymphoma Radiation Oncology Group

Richard L Bakst; Bouthaina Shbib Dabaja; Lena K Specht; Joachim Yahalom

doi:10.1016/j.ijrobp.2018.05.045

Use of Radiation in Extramedullary Leukemia/Chloroma: Guidelines From the International Lymphoma Radiation Oncology Group

Richard L Bakst, Bouthaina Shbib Dabaja, Lena K Specht, Joachim Yahalom

Department of Clinical Medicine

10 Citations (Scopus)

Abstract

Survival times for patients with leukemia generally have improved in recent decades, and this improvement has been attributed to an enhanced understanding of the genetics driving the cause of the disease and improved combinations of chemotherapy and targeted therapy. Durable control of systemic disease in blood and bone marrow has significantly improved survival, but extramedullary relapse can pose therapeutic challenges for which radiation therapy can have an important role. This report discusses the current role of radiation therapy for patients with leukemia, specifically the extramedullary manifestations of leukemia.

Original language	English
Journal	International Journal of Radiation Oncology, Biology, Physics
Volume	102
Issue number	2
Pages (from-to)	314-319
Number of pages	6
ISSN	0360-3016
DOIs	https://doi.org/10.1016/j.ijrobp.2018.05.045
Publication status	Published - 1 Oct 2018

Keywords

Acute Disease
Consensus
Humans
Leukemia/radiotherapy
Patient Positioning/methods
Practice Guidelines as Topic
Radiotherapy/adverse effects
Radiotherapy Dosage
Sarcoma, Myeloid/radiotherapy
Skin Neoplasms/radiotherapy

Access to Document

10.1016/j.ijrobp.2018.05.045

Cite this

@article{835e60c5e85c40ac903608e7301e3a9c,

title = "Use of Radiation in Extramedullary Leukemia/Chloroma: Guidelines From the International Lymphoma Radiation Oncology Group",

abstract = "Survival times for patients with leukemia generally have improved in recent decades, and this improvement has been attributed to an enhanced understanding of the genetics driving the cause of the disease and improved combinations of chemotherapy and targeted therapy. Durable control of systemic disease in blood and bone marrow has significantly improved survival, but extramedullary relapse can pose therapeutic challenges for which radiation therapy can have an important role. This report discusses the current role of radiation therapy for patients with leukemia, specifically the extramedullary manifestations of leukemia.",

keywords = "Acute Disease, Consensus, Humans, Leukemia/radiotherapy, Patient Positioning/methods, Practice Guidelines as Topic, Radiotherapy/adverse effects, Radiotherapy Dosage, Sarcoma, Myeloid/radiotherapy, Skin Neoplasms/radiotherapy",

author = "Bakst, {Richard L} and Dabaja, {Bouthaina Shbib} and Specht, {Lena K} and Joachim Yahalom",

note = "Copyright {\textcopyright} 2018. Published by Elsevier Inc.",

year = "2018",

month = oct,

day = "1",

doi = "10.1016/j.ijrobp.2018.05.045",

language = "English",

volume = "102",

pages = "314--319",

journal = "International Journal of Radiation Oncology, Biology, Physics",

issn = "0360-3016",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - Use of Radiation in Extramedullary Leukemia/Chloroma

T2 - Guidelines From the International Lymphoma Radiation Oncology Group

AU - Bakst, Richard L

AU - Dabaja, Bouthaina Shbib

AU - Specht, Lena K

AU - Yahalom, Joachim

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Survival times for patients with leukemia generally have improved in recent decades, and this improvement has been attributed to an enhanced understanding of the genetics driving the cause of the disease and improved combinations of chemotherapy and targeted therapy. Durable control of systemic disease in blood and bone marrow has significantly improved survival, but extramedullary relapse can pose therapeutic challenges for which radiation therapy can have an important role. This report discusses the current role of radiation therapy for patients with leukemia, specifically the extramedullary manifestations of leukemia.

AB - Survival times for patients with leukemia generally have improved in recent decades, and this improvement has been attributed to an enhanced understanding of the genetics driving the cause of the disease and improved combinations of chemotherapy and targeted therapy. Durable control of systemic disease in blood and bone marrow has significantly improved survival, but extramedullary relapse can pose therapeutic challenges for which radiation therapy can have an important role. This report discusses the current role of radiation therapy for patients with leukemia, specifically the extramedullary manifestations of leukemia.

KW - Acute Disease

KW - Consensus

KW - Humans

KW - Leukemia/radiotherapy

KW - Patient Positioning/methods

KW - Practice Guidelines as Topic

KW - Radiotherapy/adverse effects

KW - Radiotherapy Dosage

KW - Sarcoma, Myeloid/radiotherapy

KW - Skin Neoplasms/radiotherapy

U2 - 10.1016/j.ijrobp.2018.05.045

DO - 10.1016/j.ijrobp.2018.05.045

M3 - Review

C2 - 30191865

SN - 0360-3016

VL - 102

SP - 314

EP - 319

JO - International Journal of Radiation Oncology, Biology, Physics

JF - International Journal of Radiation Oncology, Biology, Physics

IS - 2

ER -

Use of Radiation in Extramedullary Leukemia/Chloroma: Guidelines From the International Lymphoma Radiation Oncology Group

Abstract

Keywords

Access to Document

Fingerprint

Cite this